Supernus Pharmaceuticals completed the acquisition of Adamas Pharmaceuticals for $450m.

Supernus Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, completed the acquisition of Adamas Pharmaceuticals, an innovative medicines producer, that reduces the burden of neurological diseases on patients, caregivers and society, for $450m. "This acquisition represents a significant step to further build a strong and diverse Parkinson’s disease portfolio, and aligns with our focus of acquiring value-enhancing, clinically-differentiated medicines to treat CNS diseases. We have a proven track record of strong commercial execution, and look forward to building on GOCOVRI’s growth momentum so that more patients can benefit from access to Adamas’ innovative neurological therapies," Jack Khattar, Supernus Pharmaceuticals President and CEO.